The Discovery of Weddellamycin, a Tricyclic Polyene Macrolactam Antibiotic from an Antarctic Deep-Sea-Derived Streptomyces sp. DSS69, by Heterologous Expression
Marine Drugs · 2024
DOI: 10.3390/md22040189 ↗At a glance
Journal article in Marine Drugs, 2024. Written by Lu Chen and 7 co-authors. Institution: State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China. Major MEDLINE topics: Streptomyces, Anti-Bacterial Agents, Lactams, Macrocyclic, Microbial Sensitivity Tests. Cited 17 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY 4.0). Funded by: the National Key Research and Development Program of China, the Tianjin Synthetic Biotechnology Innovation Capacity Im-provement Project, the "Major Project" of Haihe Laboratory of Synthetic Biology.
Abstract (original language)
Polyene macrolactams are a special group of natural products with great diversity, unique structural features, and a wide range of biological activities. Herein, a cryptic gene cluster for the biosynthesis of putative macrolactams was disclosed from a sponge-associated bacterium, Streptomyces sp. DSS69, by genome mining. Cloning and heterologous expression of the whole biosynthetic gene cluster led to the discovery of weddellamycin, a polyene macrolactam bearing a 23/5/6 ring skeleton. A negative regulator, WdlO, and two positive regulators, WdlA and WdlB, involved in the regulation of weddellamycin production were unraveled. The fermentation titer of weddellamycin was significantly improved by overexpression of wdlA and wdlB and deletion of wdlO. Notably, weddellamycin showed remarkable antibacterial activity against various Gram-positive bacteria including MRSA, with MIC values of 0.10–0.83 μg/mL, and antifungal activity against Candida albicans, with an MIC value of 3.33 μg/mL. Weddellamycin also displayed cytotoxicity against several cancer cell lines, with IC50 values ranging from 2.07 to 11.50 µM.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
- Haihe Laboratory of Synthetic Biology, Tianjin 300308, China.
- Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
ORCID profiles: Meifeng Tao
Funding
- the National Key Research and Development Program of China
- the Tianjin Synthetic Biotechnology Innovation Capacity Im-provement Project
- the "Major Project" of Haihe Laboratory of Synthetic Biology
- the Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project
- the “Major Project” of Haihe Laboratory of Synthetic Biology
Cite
APA
Chen, L., Liu, K., Hong, J., Cui, Z., He, W., Wang, Y., Deng, Z., & Tao, M. (2024). The Discovery of Weddellamycin, a Tricyclic Polyene Macrolactam Antibiotic from an Antarctic Deep-Sea-Derived Streptomyces sp. DSS69, by Heterologous Expression. Marine Drugs. https://doi.org/10.3390/md22040189
Vancouver
Chen L, Liu K, Hong J, Cui Z, He W, Wang Y, et al. The Discovery of Weddellamycin, a Tricyclic Polyene Macrolactam Antibiotic from an Antarctic Deep-Sea-Derived Streptomyces sp. DSS69, by Heterologous Expression. Marine Drugs. 2024. doi:10.3390/md22040189
BibTeX
@article{Chen2024,
author = {Chen, Lu and Liu, Kai and Hong, Jiali and Cui, Zhanzhao and He, Weijun and Wang, Yemin and Deng, Zixin and Tao, Meifeng},
title = {The Discovery of Weddellamycin, a Tricyclic Polyene Macrolactam Antibiotic from an Antarctic Deep-Sea-Derived Streptomyces sp. DSS69, by Heterologous Expression},
journal = {Marine Drugs},
year = {2024},
doi = {10.3390/md22040189}
}
EUVIMED